Catalyst Wire Dossier Catalyst Wire Dossier

Lutetium-177 Lu oxodotreotide

Lutetium-177 dotatate · Ipsen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium-177 Lu oxodotreotide, covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. [Phase 3]

See pricing